Loading
Berlin oncologist who led GATSBY, the trial showing that the antibody-drug conjugate T-DM1 did not beat taxane chemotherapy in previously treated HER2-positive stomach cancer.
Peter Thuss-Patience is a gastrointestinal oncologist at Charité in Berlin. He led the German AIO trial that established second-line irinotecan over best supportive care in gastric cancer, and was first author of the 2017 Lancet Oncology report of GATSBY, in which trastuzumab emtansine failed to improve survival over taxane chemotherapy in HER2-positive advanced gastric cancer after first-line treatment.
| Title | Journal | Year |
|---|---|---|
| FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma Europe PMC author record matched by affiliation (Charité Universitätsmedizin Berlin); 2016 citations on Europe PMC. | The Lancet | 2019 |
| Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Europe PMC author record matched by affiliation (Charité Universitätsmedizin Berlin); 448 citations on Europe PMC. | European Journal of Cancer | 2011 |
| A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study Europe PMC author record matched by affiliation (Charité Universitätsmedizin Berlin); 204 citations on Europe PMC. | Annals of Oncology | 2019 |
One of the most cited papers Europe PMC returns for Peter Thuss-Patience at Charité Universitätsmedizin Berlin, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
FLOT is the reference perioperative regimen for gastric and junctional adenocarcinoma, and the backbone onto which durvalumab was added in MATTERHORN.
One of the most cited papers Europe PMC returns for Peter Thuss-Patience at Charité Universitätsmedizin Berlin, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma, HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tags gastric, trialist.
Shares Charité Universitätsmedizin Berlin and the tag trialist.
Shares Gastric & gastro-oesophageal junction cancer and the tag gastric.